Candid Dish on Treatments—Round 1!
Faculty of the 22nd Annual Psychopharmacology Update Opine
Greetings, Psychiatry Newsletter Readers! This spring and summer, we are sitting down with a handful of key opinion leaders in psychiatric care for a series called Candid Dish, where we ask them what their real thoughts are on many potential up-and-coming novel treatments. For Candid Dish Round 1 of 3 in this June issue, read on to get the dish on:
- KAR-XT and emraclidine
- Glutamatergic rapid-acting antidepressants
- Cannabis—do the positives outweigh the negatives?
- Zuranolone—oral medication for post-partum depression
- Muscarinic receptor agonism as a treatment for schizophrenia
Next month’s July issue will feature Round 2 of Candid Dish, giving you the downlow from thought leaders on the following:
- Esmethadone for major depression
- Asenapine transdermal antipsychotic
- Asenapine transdermal antipsychotic
- Dexmedetomidine—sublingual alpha 2 adrenergic agonist medication for agitation
Huge thanks to these faculty for their willingness to share true opinions for Medscape’s Candid Dish:
Dr. Henry Nasrallah
Dr. Napoleon Higgins
Dr. Sidney Zisook
Dr. Joseph F. Goldberg
Dr. Leslie Citrome
Dr. Jonathan Meyer
Dr. Sagar Parikh
Dr. Christoph Correll
Don’t Miss—This Month!
June 20-24, 2024; Marriott Marquis Downtown Magnificent Mile, Chicago, Illinois
- Full 3-day meeting with interactive presentations, discussion and networking opportunities, and in addition to the scientific sessions.
- Stellar agenda! Explore the latest advances in the treatment and management of bipolar disorder, MDD, schizophrenia, PTSD, ADHD, neuropsychiatric disorders, movement disorders, as well as innovative practice approaches such as neuromodulation and digital technologies.
- Hear from internationally renowned faculty who present the most up-to-date, clinically relevant information and research.
- Take home the kind of breakthroughs that can make a difference in your patients’ lives!
- Register here
- October 25-26, 2024
- Hyatt Regency Cincinnati, OH
- Earn up to 13.25 CME/CE Credits
- From judicious psychopharmacology, evidence-based combinations, and management of treatment-resistant psychiatric disorders, to addiction and psychedelics—in addition to other urgent issues for practitioners.
- Register Now!
Check out this month’s Psych Resource section, featuring articles from Clinical Psychiatry News, Current Psychiatry, MDEdge Psychiatry, New England Journal of Medicine, and JAMA Psychiatry—check them out below!
Thank you to these thought leaders for their candid thoughts and perspectives! Please contact me at colleen@cmhadvisors.com with any comments. –Colleen Hutchinson
Candid Dish on New Treatments—Round 1!
22nd Annual Psychopharmacology Update Faculty Opine
KAR-XT and emraclidine—two antipsychotics that do not block dopamine receptors.
Dr. Leslie Citrome: Innovative and groundbreaking treatments for schizophrenia.
Dr. Joseph F. Goldberg: Fun mechanism. Let’s see if they do anything.
Dr. Napoleon Higgins: Interesting. Let's see if they work.
Dr. Jonathan Meyer: A new era for schizophrenia treatment.
Dr. Sagar Parikh: New directions for schizophrenia.
Dr. Christoph Correll: Revolutionary molecules that will help patients currently not served well.
Dr. Henry Nasrallah: A momentous paradigm shift in the pharmacotherapy of schizophrenia.
Glutamatergic rapid-acting antidepressants (dextromethorphan).
Dr. Parikh: Old medication, new tricks!
Dr. Sidney Zisook: More should be coming.
Dr. Citrome: Useful adjunct.
Dr. Goldberg: Another something to try. Fun mechanism to explain.
Dr. Higgins: Hmm... by itself or in combination?
Dr. Meyer: Glutamate dysfunction is the hallmark of depression - new strategies more directly target this problem.
Dr. Correll: An approved mechanism looking to treat treatment-resistant depression and Alzheimer's agitation.
Dr. Nasrallah: Glutamate pathways in depression are more rapid acting and more likely to achieve remission than mono-aminergic antidepressants.
Cannabis—do the positives outweigh the negatives?
Dr. Nasrallah: The negatives of cannabis far outweigh the positives: say that aloud to state and federal policy-makers.
Dr. Edwin Salsitz: Probably not.
Dr. Citrome: Too many negatives.
Dr. Zisook: Remains an interesting question.
Dr. Goldberg: Neurotoxin. What positives??
Dr. Higgins: This ain't your father's weed. This is more powerful.
Dr. Correll: No. At least not when THC is involved.
Zuranolone—oral medication for post-partum depression (via GABA-A receptors).
Dr. Citrome: Increasing awareness of PPD.
Dr. Parikh: Rapid relief when we need it most.
Dr. Zisook: Important first step – next, for MDD?
Dr. Goldberg: Killed by the FDA for MDD. Likely won't see much use.
Dr. Higgins: A promising medication for an unmet need in the population for rapid effect.
Dr. Correll: First oral neurosteroid to specifically treat postpartum depression.
Dr. Nasrallah: GABA pathways are now implicated in post-partum depression.
Muscarinic receptor agonism as a treatment for schizophrenia.
Dr. Citrome: Innovative and groundbreaking treatments for schizophrenia.
Dr. Goldberg: Fun mechanism. We'll see if they do anything.
Dr. Higgins: New mechanisms of action.
Dr. Meyer: A new era for schizophrenia treatment.
Dr. Correll: First non-postsynaptic dopamine blockers in >70 years with great promise.
Dr. Nasrallah: Good riddance to dopamine receptor blockade, its intolerable side effects, and limited efficacy on cognitive and limited symptoms.
Psychiatry Resource Section
Medscape Medical News Article: Do Antipsychotic Overprescribing Warning Letters Work?
JAMA Psychiatry Viewpoint— Biological Aging and Mental Illness—A Vicious Cycle?